Browsing Tag
Saxenda
3 posts
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
February 28, 2026
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data…
September 11, 2024
Novo Nordisk secures FDA approval for Saxenda label update targeting adolescent obesity treatment
Novo Nordisk, a global leader in diabetes and obesity care, has received approval from the US Food and…
December 6, 2020